Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ayala Pharmaceuticals, Inc. (AYLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.630.00 (0.00%)
At close: 04:00PM EST
Advertisement

Ayala Pharmaceuticals, Inc.

4 Oppenheimer Street
Rehovot 7670104
Israel
972 8 373 1541
https://www.ayalapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Dr. Roni Mamluk Ph.D.Pres, CEO & Director635.6kN/A1967
Mr. Yossi Maimon CPA, M.B.A., CPA, MBACFO, Sec. & Treasurer692.18kN/A1971
Dr. Gary B. Gordon M.D., Ph.D.Chief Medical Officer550.31kN/A1953
Ms. Irit Klipper Avni M.A.VP of HRN/AN/AN/A
Ms. Dana Gelbaum M.B.A., M.Sc.Chief Bus. OfficerN/AN/A1974
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Corporate Governance

Ayala Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement